JPH0236113B2 - - Google Patents

Info

Publication number: JPH0236113B2
Authority: JP; Japan
Prior art keywords: blood; prostaglandin; fat emulsion; processing device; blood processing
Prior art date: 1984-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

JP59071806A

Other languages

English (en)

Japanese (ja)

Other versions

JPS60215368A (ja

Inventor

Yutaka Mizushima

Yoko Shoji

Ryoichi Hasegawa

Kimihiko Matsuzawa

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Teijin Ltd

Original Assignee

Teijin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-04-12

Filing date

1984-04-12

Publication date

1990-08-15

1984-04-12 Application filed by Teijin Ltd filed Critical Teijin Ltd

1984-04-12 Priority to JP59071806A priority Critical patent/JPS60215368A/ja

1985-10-28 Publication of JPS60215368A publication Critical patent/JPS60215368A/ja

1990-08-15 Publication of JPH0236113B2 publication Critical patent/JPH0236113B2/ja

Status Granted legal-status Critical Current

Links

210000004369 blood Anatomy 0.000 claims description 49
239000008280 blood Substances 0.000 claims description 49
239000002960 lipid emulsion Substances 0.000 claims description 31
-1 prostaglandin compound Chemical class 0.000 claims description 18
239000012528 membrane Substances 0.000 claims description 13
GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 12
239000003463 adsorbent Substances 0.000 claims description 9
239000002245 particle Substances 0.000 claims description 5
150000003180 prostaglandins Chemical class 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 2
KAQKFAOMNZTLHT-OZUDYXHBSA-M prostaglandin I2(1-) Chemical compound O1\C(=C/CCCC([O-])=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-M 0.000 claims 1
230000004087 circulation Effects 0.000 description 21
230000017531 blood circulation Effects 0.000 description 15
210000001772 blood platelet Anatomy 0.000 description 12
230000000694 effects Effects 0.000 description 10
239000003146 anticoagulant agent Substances 0.000 description 6
238000000034 method Methods 0.000 description 6
239000002504 physiological saline solution Substances 0.000 description 6
208000010110 spontaneous platelet aggregation Diseases 0.000 description 6
229940127219 anticoagulant drug Drugs 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 4
238000000502 dialysis Methods 0.000 description 4
229960002897 heparin Drugs 0.000 description 4
229920000669 heparin Polymers 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
239000003549 soybean oil Substances 0.000 description 4
235000012424 soybean oil Nutrition 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
235000015112 vegetable and seed oil Nutrition 0.000 description 4
239000008158 vegetable oil Substances 0.000 description 4
239000004019 antithrombin Substances 0.000 description 3
KAQKFAOMNZTLHT-OZUDYXHBSA-N prostaglandin I2 Chemical compound O1\C(=C/CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-OZUDYXHBSA-N 0.000 description 3
239000004627 regenerated cellulose Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000005406 washing Methods 0.000 description 3
PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
241000283977 Oryctolagus Species 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000008081 blood perfusion Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
235000011187 glycerol Nutrition 0.000 description 2
238000001631 haemodialysis Methods 0.000 description 2
230000000322 hemodialysis Effects 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
ZMQAAUBTXCXRIC-UHFFFAOYSA-N safrole Chemical compound C=CCC1=CC=C2OCOC2=C1 ZMQAAUBTXCXRIC-UHFFFAOYSA-N 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
206010005133 Bleeding tendencies Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
229920001612 Hydroxyethyl starch Polymers 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
235000019482 Palm oil Nutrition 0.000 description 1
102000007327 Protamines Human genes 0.000 description 1
108010007568 Protamines Proteins 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
241000219094 Vitaceae Species 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000003266 anti-allergic effect Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
230000000702 anti-platelet effect Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000000151 deposition Methods 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
229960001123 epoprostenol Drugs 0.000 description 1
TVQGDYNRXLTQAP-UHFFFAOYSA-N ethyl heptanoate Chemical compound CCCCCCC(=O)OCC TVQGDYNRXLTQAP-UHFFFAOYSA-N 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000007789 gas Substances 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000021021 grapes Nutrition 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940088597 hormone Drugs 0.000 description 1
239000005556 hormone Substances 0.000 description 1
229940050526 hydroxyethylstarch Drugs 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000001802 infusion Methods 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000037356 lipid metabolism Effects 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
239000004533 oil dispersion Substances 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229940094443 oxytocics prostaglandins Drugs 0.000 description 1
239000003346 palm kernel oil Substances 0.000 description 1
235000019865 palm kernel oil Nutrition 0.000 description 1
239000002540 palm oil Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
231100000614 poison Toxicity 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
230000008569 process Effects 0.000 description 1
BHMBVRSPMRCCGG-OUTUXVNYSA-N prostaglandin D2 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](C\C=C/CCCC(O)=O)[C@@H](O)CC1=O BHMBVRSPMRCCGG-OUTUXVNYSA-N 0.000 description 1
150000003165 prostaglandin E1 derivatives Chemical class 0.000 description 1
150000003174 prostaglandin I2 derivatives Chemical class 0.000 description 1
229950008679 protamine sulfate Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
229940083466 soybean lecithin Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
201000005665 thrombophilia Diseases 0.000 description 1
239000003440 toxic substance Substances 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1

Landscapes

External Artificial Organs (AREA)
Materials For Medical Uses (AREA)

JP59071806A 1984-04-12 1984-04-12 改良された血液処理器及びその製造方法 Granted JPS60215368A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP59071806A JPS60215368A (ja)	1984-04-12	1984-04-12	改良された血液処理器及びその製造方法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP59071806A JPS60215368A (ja)	1984-04-12	1984-04-12	改良された血液処理器及びその製造方法

Publications (2)

Publication Number	Publication Date
JPS60215368A JPS60215368A (ja)	1985-10-28
JPH0236113B2 true JPH0236113B2 (de)	1990-08-15

Family

ID=13471177

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP59071806A Granted JPS60215368A (ja)	1984-04-12	1984-04-12	改良された血液処理器及びその製造方法

Country Status (1)

Country	Link
JP (1)	JPS60215368A (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162102A (en) *	1987-09-21	1992-11-10	Terumo Kabushiki Kaisha	Medical instrument and production thereof

1984
- 1984-04-12 JP JP59071806A patent/JPS60215368A/ja active Granted

Also Published As

Publication number	Publication date
JPS60215368A (ja)	1985-10-28

Legal Events

Date	Code	Title	Description
2004-04-12	EXPY	Cancellation because of completion of term

Publication	Publication Date	Title
Clark et al.	1999	Effect of membrane composition and structure on solute removal and biocompatibility in hemodialysis
US3725113A (en)	1973-04-03	Blood compatible microencapsulated detoxicants and method for making
US5194157A (en)	1993-03-16	Blood purifying equipment particularly for the treatment of patients suffering from renal insufficiency, and a method of producing a reinfusion liquid for haemodiafiltration (HDF)
US6627151B1 (en)	2003-09-30	Method for treatment diseases associated with a deterioration of the macrocirculation, microcirculation and organ perfusion
TW201116308A (en)	2011-05-16	An immunoactivation blood perfusion filter for the treatment of malignant tumors
EP0451429A2 (de)	1991-10-16	Einrichtung zur Blutreinigung
CN101808716A (zh)	2010-08-18	具有非离子表面活性剂的亲水膜
DE10261910A1 (de)	2004-07-15	Adsorbermaterial für Blut-, Blutplasma- und Albuminreinigungsverfahren
JP3899128B2 (ja)	2007-03-28	ヘパリンのバイオ特異的除去のための装置および方法
Mariano et al.	2004	Regional citrate anticoagulation in critically ill patients treated with plasma filtration and adsorption
WO2021015235A1 (ja)	2021-01-28	透析装置
JPH0236113B2 (de)	1990-08-15
Seidel et al.	1988	Removal of low‐density lipoproteins (LDL) and fibrinogen by precipitation with heparin at low pH: clinical application and experience
JPH0852209A (ja)	1996-02-27	血液処理のための多機能装置
de Francisco et al.	2000	Hemodiafiltration with on-line endogenous reinfusion
Inoue et al.	1981	Continuous flow membrane plasmapheresis utilizing cellulose acetate hollow fiber in hepatic failure
Ono et al.	1994	Comparison of Types of On-Line Hemodiafiltration from the Standpoint of
Ronco et al.	2004	Membranes for hemodialysis
Siemsen et al.	1978	Charcoal hemoperfusion for chronic renal failure
Frasca et al.	1988	Optimization of heparin anticoagulation during membrane plasma separation
Knisel et al.	1991	Application of a new LDL apheresis system using two dextran sulfate cellulose columns in combination with an automatic column‐regenerating unit and a blood cell separator
Whittlesey et al.	1988	Is heparin necessary for extracorporeal circulation?
Vanholder et al.	1990	Single needle haemodialysis
Markert et al.	1988	Neutrophil functions during hemodialysis
Eriksson et al.	1989	Lipid lowering in severe familial hypercholesterolaemia: efficacy and safety of a new regenerating system for selective apheresis of apolipoprotein B‐containing lipoproteins